Business
Tenax Announces Issuance of U.S. Patent Covering Use of IV Levosimendan in Pulmonary Hypertension with Heart Failure with Preserved Ejection Fraction (PH-HFpEF)
Patent provides intellectual property protection until December 2040PH-HFpEF affects more than 1,600,000 North Americans, with estimates indicating a
About this update from Tenax Therapeutics, Inc.
[{"type":"text","content":"Patent provides intellectual property protection until December 2040PH-HFpEF affects more than 1,600,000 North Americans, with estimates indicating a prevalence of more than 2,000,000 patients by 2030There are currently no FDA approved treatments for PH-HFpEFLevosimendan combines two MoAs that, for the first time, specifically target the symptoms PH-HFpEF patients suffer. CHAPEL HILL, N.C., March 22, 2023 (GLOBE NEWSWIRE) -- Tenax Therapeutics, Inc. (Nasdaq: TENX), a specialty pharmaceutical company focused on identifying, developing and commercializing products that address cardiovascular and pulmonary diseases with high unmet medical need, announced today that the Company has been issued a patent by the United States Patent and Trademark Office (USPTO) with claims covering the use of IV levosimendan in the treatment of pulmonary hypertension associated with HFpEF. U.S. Patent No. 11,607,412 is titled “Levosimendan For Treating Pulmonary Hypertension With Heart Failure With Preserved Ejection Fraction (PH-HFpEF).” The patent term expires December 2040 and provides the Company substantial added intellectual property (IP) protection for the use of levosimendan. The newly issued patent expands upon the Company’s existing IP for levosimendan, which includes U.S. Patent No. 11,213,524, issued in January 2022, covering all medical uses of the subcutaneous formulation of levosimendan in humans. Chris Giordano, Tenax Therapeutics’ President and Chief Executive Officer, stated, “Tenax is building a solid patent estate surrounding levosimendan. The issuance of U.S. Patent 11,607,412 substantially strengthens this IP foundation and we believe will serve as an important strategic asset as we advance levosimendan through the clinic and also consider select partnering opportunities. The USPTO’s decision to grant a patent for the use of IV levosimendan for the specific indication of PH-HFpEF confirms the proprietary nature of the work Tenax is doing and provides precedent for action in our pending U.S. patent application that covers the oral formulation (TNX-103) in the same patients.” As demonstrated by the results of the HELP Study, levosimendan is a unique and promising cardiovascular drug with the potential to help patients who suffer from PH-HFpEF, who currently have no FDA approved therapies. The HELP Study data showed that levosimendan...